{"nctId":"NCT00092443","briefTitle":"Dose Confirmation Efficacy Study (V260-007)","startDateStruct":{"date":"2002-09"},"conditions":["Rotavirus Infections"],"count":1312,"armGroups":[{"label":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","type":"EXPERIMENTAL","interventionNames":["Biological: RotaTeq™, rotavirus vaccine, live, oral, pentavalent"]},{"label":"Placebo matching RotaTeq™","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Comparator: Placebo matching RotaTeq™"]}],"interventions":[{"name":"RotaTeq™, rotavirus vaccine, live, oral, pentavalent","otherNames":["V260"]},{"name":"Comparator: Placebo matching RotaTeq™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants\n\nExclusion Criteria:\n\n* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery\n* Known or suspected problems with immune system\n* Fever at time of immunization\n* Prior administration of a rotavirus vaccine\n* History of known prior rotavirus disease\n* Chronic diarrhea, or failure to thrive","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.","description":"G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With ≥3 Fold Rise in Antibody Titer","description":"Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"15","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"1","spread":null},{"groupId":"OG009","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":649},"commonTop":["Pyrexia","Irritability","Upper respiratory tract infection","Otitis media","Diarrhoea"]}}}